Aytu BioPharma Statistics
Total Valuation
Aytu BioPharma has a market cap or net worth of $16.17 million. The enterprise value is $12.68 million.
| Market Cap | 16.17M |
| Enterprise Value | 12.68M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Aytu BioPharma has 5.57 million shares outstanding. The number of shares has increased by 77.40% in one year.
| Shares Outstanding | 5.57M |
| Shares Change (YoY) | +77.40% |
| Shares Change (QoQ) | +0.65% |
| Owned by Insiders (%) | 3.49% |
| Owned by Institutions (%) | 31.78% |
| Float | 3.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 5.78 |
| PS Ratio | 0.16 |
| Forward PS | 0.41 |
| PB Ratio | 0.49 |
| P/FCF Ratio | 2.65 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 2.07 |
Financial Position
The company has a current ratio of 1.11, with a Debt / Equity ratio of 0.49.
| Current Ratio | 1.11 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.62 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.50% and return on invested capital (ROIC) is -17.85%.
| Return on Equity (ROE) | -49.50% |
| Return on Assets (ROA) | -13.10% |
| Return on Capital (ROIC) | -17.85% |
| Revenue Per Employee | $656,653 |
| Profits Per Employee | -$119,980 |
| Employee Count | 150 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 2.79 |
Taxes
In the past 12 months, Aytu BioPharma has paid $828,000 in taxes.
| Income Tax | 828,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +19.51% in the last 52 weeks. The beta is -1.26, so Aytu BioPharma's price volatility has been lower than the market average.
| Beta (1Y) | -1.26 |
| 52-Week Price Change | +19.51% |
| 50-Day Moving Average | 3.00 |
| 200-Day Moving Average | 2.53 |
| Relative Strength Index (RSI) | 48.51 |
| Average Volume (30 Days) | 20,911 |
Short Selling Information
The latest short interest is 402,507, so 7.23% of the outstanding shares have been sold short.
| Short Interest | 402,507 |
| Short Previous Month | 360,854 |
| Short % of Shares Out | 7.23% |
| Short % of Float | 10.60% |
| Short Ratio (days to cover) | 18.63 |
Income Statement
In the last 12 months, Aytu BioPharma had revenue of $98.50 million and -$18.00 million in losses. Loss per share was -$3.85.
| Revenue | 98.50M |
| Gross Profit | 62.29M |
| Operating Income | -8.73M |
| Pretax Income | -17.17M |
| Net Income | -18.00M |
| EBITDA | -8.45M |
| EBIT | -17.17M |
| Loss Per Share | -$3.85 |
Balance Sheet
The company has $19.53 million in cash and $16.04 million in debt, giving a net cash position of $3.49 million or $0.63 per share.
| Cash & Cash Equivalents | 19.53M |
| Total Debt | 16.04M |
| Net Cash | 3.49M |
| Net Cash Per Share | $0.63 |
| Equity / Book Value | 32.85M |
| Book Value Per Share | 5.90 |
| Working Capital | 7.18M |
Cash Flow
| Operating Cash Flow | 6.11M |
| Capital Expenditures | n/a |
| Free Cash Flow | 6.11M |
| FCF Per Share | $1.11 |
Margins
Gross margin is 63.24%, with operating and profit margins of -8.86% and -18.27%.
| Gross Margin | 63.24% |
| Operating Margin | -8.86% |
| Pretax Margin | -17.43% |
| Profit Margin | -18.27% |
| EBITDA Margin | -8.58% |
| EBIT Margin | -17.43% |
| FCF Margin | 6.21% |
Dividends & Yields
Aytu BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -77.40% |
| Shareholder Yield | -77.40% |
| Earnings Yield | -111.30% |
| FCF Yield | 37.80% |
Analyst Forecast
The average price target for Aytu BioPharma is $12.50, which is 330.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.50 |
| Price Target Difference | 330.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 2.87% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 6, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 6, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Aytu BioPharma has an Altman Z-Score of -2.85 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.85 |
| Piotroski F-Score | 5 |